Cargando…

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.

Detalles Bibliográficos
Autores principales:	Bachert, Claus, Fokkens, Wytske, Hellings, Peter, Scadding, Glenis, Munzel, Ullrich, Mullol, Joaquim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493527/ http://dx.doi.org/10.1186/2045-7022-5-S4-P38

Ejemplares similares

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
por: Bousquet, Jean, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
por: Bachert, Claus, et al.
Publicado: (2013)

A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
por: Fokkens, Wytske, et al.
Publicado: (2015)

A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
por: Hellings, Peter W., et al.
Publicado: (2015)

Diagnostic tools in Rhinology EAACI position paper
por: Scadding, Glenis, et al.
Publicado: (2011)

MP29-02* reduces eosinophil survival induced by epithelial cell secretions from nasal mucosa
por: Roca-Ferrer, Jordi, et al.
Publicado: (2015)

Identification of gaps in the current allergic rhinitis guidelines and how these can be filled
por: Bousquet, Jean, et al.
Publicado: (2015)

Deposition characteristics of a new allergic rhinitis nasal spray (MP29-02*) in an anatomical model of the human nasal cavity
por: D’Addio, Alex, et al.
Publicado: (2015)

A New Grand Challenge in Rhinology: An Intranasal COVID Vaccine
por: Scadding, Glenis Kathleen
Publicado: (2022)

MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis
por: van Weissenbruch, Ranny, et al.
Publicado: (2020)

A new AR therapy (MP29-02*): all of ARIA in one puff
por: Mösges, Ralph, et al.
Publicado: (2015)

The ‘GA²LEN Sinusitis Cohort’: an introduction
por: Vandeplas, Griet, et al.
Publicado: (2015)

Real-life effectiveness of a new allergic rhinitis therapy (MP29-02*) in Sweden
por: Stjärne, Pär, et al.
Publicado: (2015)

Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
por: Price, David, et al.
Publicado: (2020)

The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey
por: Price, David, et al.
Publicado: (2015)

A EUFOREA comment on a lost comorbidity of asthma
por: Conti, Diego M., et al.
Publicado: (2023)

PD15 - MP29-02 effectively relieves both nasal and ocular symptoms in adolescents aged 12-17 years: results from a meta-analysis of 4 randomised controlled Seasonal Allergic Rhinitis (SAR) trials
por: Valovirta, Erkka, et al.
Publicado: (2014)

Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy
por: Bhagwat, Priya, et al.
Publicado: (2019)

Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options
por: Deer, Timothy R, et al.
Publicado: (2019)

Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible
por: Pena, M J, et al.
Publicado: (2018)

The Emergence of Resistance Under Firstline INSTI Regimens
por: Xie, Zhiman, et al.
Publicado: (2022)

Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis
por: Valero, Antonio, et al.
Publicado: (2020)

P07 - Treatment load in the therapy management of allergic rhinitis: a UK retrospective database study
por: Carter, Victoria, et al.
Publicado: (2014)

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
por: De Jong, Hilda J.I., et al.
Publicado: (2020)

Correction to: Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Management of persistent allergic rhinitis: evidence-based treatment with levocetirizine
por: Mullol, Joaquim, et al.
Publicado: (2005)

Capsaicin for Rhinitis
por: Fokkens, Wytske, et al.
Publicado: (2016)

The effect of MP29-02* is mediated via bitter taste receptors (TAS2R)
por: Ekstedt, Sandra, et al.
Publicado: (2015)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]
por: Scadding, Glenis K, et al.
Publicado: (2023)

A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease
por: Pendolino, Alfonso Luca, et al.
Publicado: (2021)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
por: Van Broeck, Dorien, et al.
Publicado: (2023)

Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy
por: Ruggiero, Alessandra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g5289nvo752ku98vm3ococsmf6